ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Clinton Proposes $1.15 Billion Increase For NIH; Support For Cancer Research

January 30, 1998

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

January 31, 2014

DCT Board Approves Management Support, Drug Storage Concepts

March 3, 1989

Cancer death rate dropping 1.1 percent a year, annual report finds.

October 7, 2005

Directory Of NCI Numbers Available

March 22, 1985

NCI, CDC To Collaborate On Surveillance System.

March 24, 2000